Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EN001 Safety and Dose Study in Duchenne Muscular Dystrophy
NCT05338099Phase 1Completed
- Sponsor
- ENCell
- Start
- Jan 2022
- Primary completion
- Dec 2022
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of EN001 in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by ENCell. Primary endpoints: Adverse Events (AEs)/Serious Adverse Events (SAEs) related to investigational product at 12 weeks, Dose-limiting toxicity at 2 weeks and 5 more. Started Jan 2022; status: completed.
02
Drugs
EN001
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05338099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05338099.